Stocktoria

Allogene Therapeutics, Inc. ALLO

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-11
Chart by TradingView
2/9
Piotroski F — financial health
-13.1
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$0$22,000$95,000$156,000$114.1M
Operating income-$209.3M-$273.2M-$327.7M-$335.5M-$180.2M
Net income-$190.9M-$257.6M-$327.3M-$340.4M-$182.1M
Operating cash flow-$149.2M-$200.3M-$237.7M-$220.5M-$184.8M
Free cash flow-$149.6M-$201.0M-$239.2M-$225.7M-$206.3M
Total assets$415.9M$548.7M$642.8M$821.6M$1.0B
Total liabilities$123.4M$126.5M$130.6M$154.7M$122.2M
Shareholders' equity$292.5M$422.2M$512.2M$666.9M$925.2M
Ratios
Operating margin-1241813.6%-344986.3%-215087.2%-157.9%
Net margin-1170863.6%-344489.5%-218214.1%-159.6%
FCF margin-913609.1%-251841.1%-144685.9%-180.8%
Return on assets-45.9%-46.9%-50.9%-41.4%-17.5%
Return on equity-65.3%-61.0%-63.9%-51.0%-19.7%
Current ratio7.938.5412.389.849.78
Revenue growth-100.0%-76.8%-39.1%-99.9%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC2,139,328$5.2M
Point72 Asset Management, L.P.221,335$540,057

Why these scores methodology →

Piotroski F-score: 2/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -13.1 (distress)

  • Working capital / assets 0.542
  • Retained earnings / assets -4.835
  • EBIT / assets -0.503
  • Equity / liabilities 2.371

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001737287 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.